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Abstract
Title—Utility of a precursor-to-product ratio in the evaluation of presumptive positives in 
newborn screening of congenital adrenal hyperplasia.
Objective—Screening for Congenital Adrenal hyperplasia (CAH) caused by 21-α hydroxylase 
deficiency is challenging because factors such as prematurity and stress increase intermediate 
steroid metabolite levels in newborn infants. The objective of this study was to explore the use of 
the 17-OHP/11-deoxycortisol ratio as an adjunct measure in the follow-up evaluation of infants 
with presumptive positive newborn screens for CAH to distinguish between infants with no 
disorder and those with CAH.
Study Design—This was a retrospective cohort study of infants with presumptive positive 
newborn screens for CAH. The precursor-to-product ratio of 17-OHP/11-deoxycortisol was 
compared between infants with no disorder (n=47) and infants with CAH (n=5).
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Results—The CAH infants had higher 17-OHP/11-deoxycortisol ratios than infants with no 
disorder, 26 (18-58) and 1.05 (0.69-1.46), respectively, p<0.05. Among infants with no disorder, 
higher levels of serum 17-OHP did not reflect higher ratios, indicating sufficient enzyme activity.
Conclusions—The results suggest that a low 17-OHP/11-deoxycortisol ratio represents 21-α 
hydroxylase sufficiency among presumptive positives in newborn screening of CAH.
Introduction
The newborn screening of congenital adrenal hyperplasia (CAH) in California was 
implemented in 2005 and is currently mandated in all states. CAH is an autosomal recessive 
inherited disease and has an incidence of about 1 in 17,000 1. CAH caused by 21-α 
hydroxylase deficiency accounts for about 90% of the diagnosed cases. The salt-wasting 
form of 21-α hydroxylase deficiency comprises 75% of these cases and is potentially lethal 
if not treated early2, 3. Under normal physiologic conditions, the enzyme 21-α hydroxylase 
catalyzes the conversion of 17 α-hydroxyprogesterone (17-OHP) to 11-deoxycortisol, and 
therefore its deficiency in CAH leads to accumulation of 17-OHP. Newborn screening 
(NBS) programs measure 17-OHP to screen for CAH, however, the frequency of false 
positive test results remains a problem.
Serum values of adrenal steroids in newborn infants are influenced by many factors such as 
neonatal stress, assay conditions, maternal steroid treatment, immature adrenal axis, and 
immature renal functioning4, 5, 6, 7. Thus, serum steroid values are not normally distributed, 
and cut-off values for 17-OHP in premature infants are higher than values for term 
infants 5, 8. The variability of steroid values in the newborn is the underlying reason for the 
large number of false positive results found in newborn screening, which utilizes the method 
of time-resolved fluoroimmunoassay. Application of age- and weight-based cutoffs, and 
second-tier screening methods have been unsuccessful in minimizing the number of false 
positive reports 9. When an infant screens positive for CAH, the standard of practice is to 
draw blood for confirmatory measurement of serum 17-OHP by liquid chromatography 
tandem mass spectrometry (LC-MS/MS). These results are again subject to cut-offs based 
on gestational age. The abundance of false positives for CAH in newborn screening 
continues to be a dilemma for the clinician and family because of this need for repeat 
testing. Repeat testing increases the burden of health care costs and can result in more 
parental anxiety2.
The current method of screening examines 17-OHP as a single metabolite within a larger 
network of interconnecting pathways, and thus does not provide an accurate reflection of 
enzyme activity. Alternatively, when evaluating the metabolite directly before (17-OHP) and 
after (11-deoxycortisol) the enzyme block, expressed as a ratio, a more informative 
depiction of enzyme activity may be observed. When 21-α-hydroxylase is deficient, 17-
OHP cannot be converted to its product 11-deoxycortisol and thus 17-OHP rises 
substantially while 11-deoxycortisol values remain low. Therefore, in patients with CAH, 
one would expect a high ratio of 17-OHP/11-deoxycortisol. Our group has previously shown 
that the precursor-to-product ratio of 17 α-hydroxyprogesterone/11-deoxycortisol in 
newborn dried blood spots accurately reflects 21-α-hydroxylase activity in newborns with 
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and without CAH 10. Therefore, there may be potential for using the 17-OHP/11-
deoxycortisol ratio as a clinical tool in the evaluation of presumptive positive screens for 
CAH.
We hypothesize that there is a greater variability of 17-OHP levels compared to the ratio of 
17-OHP/11-deoxycortisol, and that the ratio may prove to be useful clinically to reduce the 
need for repeat confirmatory testing. The objective of this study was to explore whether the 
17-OHP/11-deoxycortisol ratio in infants with presumptive positive NBS results may 
demonstrate a difference between infants with no disorder versus those with CAH. Infants 
with CAH are expected to have higher ratios, and conversely infants with no disorder are 
expected to have ratios within a published reference range.
Methods
This is a retrospective cohort study examining presumptive positive cases of CAH, including 
those with CAH, and those with no disorder. Human Subjects approval was obtained from 
the Human Subjects Committee at the Los Angeles Biomedical Research Institute at Harbor-
UCLA Medical Center.
A chart review process identified a total of 63 presumptive positive CAH cases referred to 
the Regional Newborn Screening Referral Center at Harbor-UCLA Medical Center between 
October 2010 and June 2013. These included cases from surrounding community hospitals. 
Data was limited to available information collected by the NBS program and entered into the 
local database. Subjects were included in the study analysis (n=47) if they met the following 
criteria: age of screen >24 hours after birth, and availability of serum confirmatory 17-OHP 
and 11-deoxycortisol measurements drawn at the same time. Subjects were excluded if 
steroid therapy was initiated prior to confirmatory testing. Maternal data including steroid 
therapy prior to delivery was not recorded for all cases and therefore was not included in the 
subject selection process. In addition, the clinical status (i.e. intubated, septic, or healthy, 
prior transfusions) of each subject during the collection process was not always known and 
therefore is not addressed in this study.
The primary outcome variables examined were serum 17-OHP, 11-deoxycortisol, and the 
17-OHP/11-deoxycortisol ratio. The 17-OHP/11-deoxycortisol ratios were calculated from 
the reference laboratory values of 17-OHP and 11-deoxycortisol, which were reported in 
ng/dL. (To determine ratios based on nmol/L, one would multiply each ratio based on the 
ng/dl results by 1.048.).
Statistical analyses were performed using Excel, SigmaPlot and SYSTAT software. The 17-
OHP, 11-deoxycortisol concentrations, and 17-OHP/11-deoxycortisol ratios were examined 
in frequency distribution graphs. Tests for normality were performed using the Shapiro-Wilk 
test. Comparisons between groups were made using the two-sided t-test or the Kruskal-
Wallis test, with p<0.05 considered statistically significant. Normally distributed data is 
presented as the mean ± the standard error of the mean, while non-parametric data is 
presented as the median and interquartile ranges (25%–75%). Relationships between the 
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primary outcome variables and infant characteristics were determined using Spearman’s 
correlations.
Results
The subject characteristics of the no disorder group (n=47) and the positive CAH group 
(n=5) are displayed in Table 1. Infants with no disorder (n=47) were younger than those with 
CAH, (p<0.001), and correspondingly had lower birth weights (p< 0.001). Among the 
infants with no disorder, males and females did not differ in comparison of hour of 
screening, NBS 17-OHP, confirmatory 17-OHP, confirmatory 11-deoxycortisol, and the 17-
OHP/11-deoxycortisol ratios. In comparison to CAH infants, the infants with no disorder 
had lower values of NBS 17-OHP (p < 0.01) and confirmatory 17-OHP levels (p <0.05), but 
no difference in confirmatory 11-deoxycortisol concentrations. Infants with no disorder 
exhibited lower 17-OHP/11 deoxycortisol ratios (Figure 1) than infants with CAH (p < 
0.05), with no overlap between groups
Figure 2 shows the frequency distribution of the 17-OHP concentrations from the newborn 
screening dried blood test superimposed upon the distribution of the concentrations from 
serum confirmatory testing. There is generally no overlap in the two sets of values 
suggesting a rapid maturation of the pituitary adrenal axis in postnatal life between the time 
points of newborn screening and confirmatory testing.
Figure 3A shows the frequency distribution of 17-OHP serum values from confirmatory tests 
among the presumptive positive infants, with the corresponding 17-OHP/11-deoxycortisol 
ratios noted above the bars for the top quartile of 17-OHP. In parallel, Figure 3B, shows the 
frequency distribution of ratios with the corresponding 17-OHP values noted above the top 
quartile of ratios. In the highest quartile of 17-OHP (Figure 3A), the corresponding ratios 
fell below the top quartile values of the ratio (<1.625) except for two values. Thus, an 
elevated 17-OHP value alone does not correspond to lower enzyme activity based on the 
precursor-to-product ratios.
Correlations were performed between 17-OHP or 11-deoxycortisol and infant characteristics 
(Figure 4). 17-OHP negatively correlated with gestational age and birth weight, but 
positively correlated with hour of screen, which was consistent with findings of previous 
studies 11. Similarly, 11-deoxycortisol negatively correlated with gestational age and birth 
weight, and positively correlated with hour of screen. No other correlations of significance 
were found in the other data categories, including between NBS 17-OHP and serum 
confirmatory 17-OHP.
Discussion
The main objective of newborn screening for CAH is to make an early diagnosis in order to 
prevent or provide timely lifesaving treatment of salt-wasting crisis in 21-α-hydroxylase 
deficiency 12, 13. The problem of false positives from NBS frequently occurs, despite efforts 
in applying age and weight-based cutoffs, and 2nd tier screening. Multiple factors 
contributing to false positive results include differences in physiology between premature 
and term infants, maternal conditions and neonatal stress 9, 14. In this retrospective study, we 
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demonstrate that the confirmatory 17-OHP/11 deoxycortisol precursor-product ratios differ 
widely between CAH infants and those with false positive newborn screens. The ratio may 
be helpful especially in the evaluation of premature infants.
The infants with no disorder tended to be premature in comparison to the term infants with 
CAH. Our data exhibited corresponding biochemical differences between the two groups 
(Table 1 and Figure 1), consistent with a delay in maturation of the 21-α-hydroxylase 
enzyme in prematurity 5, 15. The 17-OHP/11-deoxycortisol ratio is a measure of 21 α-
hydroxylase enzyme activity under steady state10. Because of the inability to convert 17-
OHP to 11-deoxycortisol in infants with CAH, a disproportionate elevation in 17-OHP with 
respect to 11-deoxycortisol was expected, despite no difference observed in 11-
deoxycortisol between the groups. As a result, the CAH infants demonstrated a concomitant 
elevation of the 17-OHP/11-deoxycortisol precursor-to-product ratio. In contrast, infants 
with no disorder demonstrated low ratios, likely reflecting a stabilization, or possibly even a 
decreasing ratio, as enzyme activity matures.
We have previously suggested establishing cut-off values for the 17-OHP/11-deoxycortisol 
ratio to be used in the newborn screening of CAH16. Reference ranges of steroid precursor-
to-product ratios have already been published by Quest Diagnostics, including 17-OHP/11-
deoxycortisol ratios in premature (26–28 wk: 0.4–2.4; 34–36 wk: 0.9–4.8) and term infants 
(0.4-3.1)17. All of our subjects with no disorder had ratios below the upper limits, with the 
highest ratio resulting from a 34-week old infant (ratio 3.6). In our cohort, 28% (13/47) 
required repeat confirmatory testing due to borderline or persistently elevated confirmatory 
17-OHP levels, however their ratios ranged from 0.41 to 1.95. Application of the 17-
OHP/11-deoxycortisol ratio could have reduced the need for repeat confirmatory testing in 
these cases, thus reducing health care costs and relieving parental anxiety. Therefore, we 
propose that the 17-OHP/11 deoxycortisol has potential for clinical utility during post-NBS 
confirmatory testing. Whether the ratio could also be useful in second-tier newborn 
screening would require additional research, as reporting of 11-deoxycortisol in the second-
tier metabolite panel has only recently begun.
A limitation of this study was the small sample size based at one Newborn Screening 
Referral Center for the infant cohort. In addition, limited clinical data for this retrospective 
analysis did not allow for adjustment of potential perinatal confounding factors that may 
influence steroidogenesis 4, 5, 6. In order to establish use of the ratio in ruling out the 
diagnosis of CAH, a larger-scale study that includes larger sample sizes of CAH infants and 
infants with false positive tests should be conducted.
Conclusions
The precursor-to-product ratio (17-OHP/11-deoxycortisol) in newborn dried blood spots was 
previously demonstrated to reflect 21-α-hydroxylase activity 10. The present study illustrates 
a wide difference in the serum confirmatory 17-OHP/11-deoxycortisol ratios between 
infants with and without CAH who tested positive on newborn screening. Further studies on 
application of the 17-OHP/11-deoxycortisol precursor-to-product ratio in NBS confirmatory 
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testing are needed. The ratio may be especially helpful in the evaluation of premature 
infants.
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Figure 1. Dot plot of 17-OHP/11-deoxycortisol ratios in infants with congenital adrenal 
hyperplasia (CAH) (n=5) and with no disorder (n=47)
The medians, and the limits of the 25% to 75% interquartile ranges are represented by dark 
and thin lines, respectively. Ratios were compared with the Kruskal-Wallis test. Infants with 
CAH [26 (18 -58)] had higher ratios than infants with no disorder [1.05 (0.69 – 1.46)], 
p<0.05.
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Figure 2. Distribution graph of 17-OHP values from NBS and confirmatory serum testing in 
infants with no disorders
Data is presented in nmol/L. The solid bars represent NBS 17-OHP values, while the striped 
bars represent serum confirmatory values.
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Figure 3. Distribution graphs of confirmatory serum 17-OHP values and 17-OHP/11-
deoxycortisol ratios for infants with no disorder (n=47)
(A) Distribution graph of confirmatory 17-OHP values (nmol/L). The numbers above the 
bars indicate the corresponding 17-OHP/11-deoxycortisol ratios among the top 25% of 17-
OHP values. (B) Distribution of 17-OHP/11-deoxycortisol ratios, with the corresponding 
NBS 17-OHP values (nmol/L) noted above the top 25% of ratios.
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Figure 4. Spearman correlation graphs for 17-OHP and 11-deoxycortisol values vs. infant 
characteristics
Spearman’s rho(ρ) and p values are noted above each graph for the following: (A) 
gestational age vs. confirmatory serum 17-OHP, (B) birth weight vs confirmatory serum 17-
OHP, (C) hour of screen vs. confirmatory serum 17-OHP, (D) gestational age vs 
confirmatory serum 11-deoxycortisol, (E) birth weight and confirmatory serum 11-
deoxycortisol, and (F) hour of screen vs confirmatory serum 11-deoxycortisol.
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Table 1
Characteristics of Study Subjects.
No Disorder (n=47) CAH
(n=5)
P-value
Gender M: 53%, F: 47% M:80%, F:20% NS1
Gestational Age (weeks) 30.4 ± 0.62 39.6 ± 0.68 < 0.001
Birth Weight (grams) 1335 (1040 – 2122) 3500 (3395 – 4191) < 0.001
Hour of Screen (hours) 44 (31 – 57) 24 (17.5 – 30.5)3 < 0.01
NBS Dried Blood Spot 17-OHP (nmol/L) 83 (63–101) 593 (399–633) < 0.01
Confirmatory serum 17-OHP (nmol/L) 8 (4–13) 570 (379–662) < 0.05
Confirmatory serum 11-deoxycortisol (nmol/L) 6 (4–12) 14 (8–23) 0.26
1NS, not significantly different; NBS, newborn screen
2Normally distributed data is presented as the mean ± the standard error of the mean. Non-parametric data is presented by the median followed by 
the 25%–75% interquartile ranges enclosed in parentheses.
3
n=4 for CAH subjects hour of screen due to inability to obtain one subject's hour of screen from NBS.
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